Abstract

The COVID-19 (SARS-CoV-2) pandemic, which started in Wuhan, China, in December 2019, caused the infection of millions of people around the world and the death of many people. Many countries started vaccine studies in order to reduce the speed of the pandemic, and the vaccines produced were given emergency use approval and were quickly administered in the countries. It is reported in the literature that axillary lymphadenopathy develops as an immune reaction following the COVID-19 vaccine. But in this case report, additional to that, zona zoster infection also developed after vaccination. The aim of this study is to contribute to the literature in terms of immune-mediated infection and immune response.

We presented a 36-year-old female patient who applied to the Family Medicine Polyclinic 3 days after the third dose of Pfizer-BioNTech. In physical examination, together with the inflammation of the lymph nodes in both axillae, there were also vesicles in the back region which were signs of Zona Zoster disease, a skin infection that develops due to the latent Varicella Zoster virus. Oral acyclovir was the main treatment but in additional to that topical administration for herpes zoster and antibiotherapy for lymphadenopathy were prescribed. The vesicles regressed three days after treatment and were fully healed within a week.